April 2017: Inventiva Hits Clinical Milestone with Enrollment of 100th Patient in IVA337 Phase 2b FASST Trial in Systemic Sclerosis (SSc)
The article « Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis », written by Prof. Yannick Allanore’s team, has been published in the Annals of the Rheumatic Diseases (Online First, 9 March 2016).
This article reports a study of the antifibrotic effects of IVA337, using a bleomycin-induced mouse model of dermal fibrosis.
In conclusion, the findings of this study indicate that simultaneous activation of all three PPAR isoforms exerts a dampening effect on inflammation and fibrosis, making IVA337 a potentially effective therapeutic candidate in the treatment of fibrotic diseases including SSc.
Download the article for free
Inventiva rewarded for its innovative approach with IVA337 at the 4th Systemic Sclerosis World Congress in Lisbon, February 2016.
European Patient associations federation:
Clinical trials databases: